Coherus Oncology, Inc. (CHRS)
1.04
-0.03
(-2.80%)
USD |
NASDAQ |
Oct 12, 12:02
Coherus Oncology Price to Book Value : 2.641 for Oct. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 2.717 |
| October 08, 2026 | 2.717 |
| October 07, 2026 | 2.564 |
| October 06, 2026 | 2.615 |
| October 05, 2026 | 2.844 |
| October 02, 2026 | 2.945 |
| October 01, 2026 | 2.945 |
| September 30, 2026 | 3.072 |
| September 29, 2026 | 2.996 |
| September 28, 2026 | 2.894 |
| September 25, 2026 | 2.869 |
| September 24, 2026 | 2.971 |
| September 23, 2026 | 3.199 |
| September 22, 2026 | 3.301 |
| September 21, 2026 | 3.478 |
| September 18, 2026 | 3.428 |
| September 17, 2026 | 3.123 |
| September 16, 2026 | 3.098 |
| September 15, 2026 | 3.377 |
| September 14, 2026 | 3.631 |
| September 11, 2026 | 3.377 |
| September 10, 2026 | 3.402 |
| September 09, 2026 | 3.352 |
| September 08, 2026 | 3.478 |
| September 04, 2026 | 3.605 |
| Date | Value |
|---|---|
| September 03, 2026 | 3.478 |
| September 02, 2026 | 3.605 |
| September 01, 2026 | 3.478 |
| August 31, 2026 | 3.428 |
| August 28, 2026 | 3.58 |
| August 27, 2026 | 3.707 |
| August 26, 2026 | 3.682 |
| August 25, 2026 | 3.478 |
| August 24, 2026 | 3.453 |
| August 21, 2026 | 3.605 |
| August 20, 2026 | 3.352 |
| August 19, 2026 | 3.377 |
| August 18, 2026 | 3.402 |
| August 17, 2026 | 2.920 |
| August 14, 2026 | 3.047 |
| August 13, 2026 | 2.894 |
| August 12, 2026 | 2.971 |
| August 11, 2026 | 3.072 |
| August 10, 2026 | 3.148 |
| August 07, 2026 | 3.225 |
| August 06, 2026 | 3.212 |
| August 05, 2026 | 3.682 |
| August 04, 2026 | 3.758 |
| August 03, 2026 | 3.656 |
| July 31, 2026 | 3.58 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Enanta Pharmaceuticals, Inc. | 3.535 |
| ACADIA Pharmaceuticals, Inc. | 2.582 |
| Alnylam Pharmaceuticals, Inc. | 22.62 |
| Anika Therapeutics, Inc. | 1.928 |
| Savara, Inc. | 6.977 |
Price to Book Value Related Metrics
| PS Ratio | 2.694 |
| Price | 1.04 |
| Earnings Yield | -98.19% |
| Market Cap | 160.65M |